ClinicalTrials.gg
CompletedNCT04793087COCONUpdated Mar 15, 2021

Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis (COCON)

An observational study in Optic Neuritis and Multiple Sclerosis, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-15.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Study summary

3D FLAIR, 3D T1 FAT SAT, coronal T2 and coronal T1 dixon sequences were usually used to assess visual deficits in MRI. Optic nerve examination is preferably performed using a coronal T2 sequence in order to detect a hypersignal suggestive of inflammation whereas brain examination is preferably performed using a 3D T1 sequence to highlight signs of spatial dissemination and lesions suggestive of multiple slerosis (MS). No study has yet investigated the detection capabilities of 3D T1 for the detection of optic nerve inflammation. The objective of this retrospective study was to determine whether a single 3D T1 sequence allows simultaneous exploration of the optic nerve and the brain for the positive diagnosis of optic neuropathy and/or MS.

02

Conditions studied

  • Optic Neuritis
  • Multiple Sclerosis
03

In context

Optic Neuritis

88 studies on the registry are indexed under Optic Neuritis; 16 are open to participants now.

This study's enrollment of 1,200 is above the median of 150 across 25 observational studies indexed under Optic Neuritis.

Browse Optic Neuritis studies →

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with visual acuity loss explored by MRI between january 2018 and january 2020

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • Decrease in visual acuity explored in MRI between january 2018 and january 2020

Exclusion criteria

Exclusion Criteria:

  • Past history of episode of Optic neuritis
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,200 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testMagnetic Resonance Imaging

    Comparing 3D T1 versus coronal T1 MRI in detecting Optic Neuritis

06

What researchers measure

Primary outcomes

  1. Detection of optic neuropathies using MRI

    MRI comparison of the diagnostic performance of the 3D T1 sequence and the T1 coronal in the detection of optic neuropathies.

    Time frame: 1 hour

07

Study locations

1 site
  • Hôpital Fondation Adolphe de Rothschild
    Paris, Ile-de-France 75019, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jan 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2021
First posted
Mar 11, 2021
StartActual
Jan 1, 2018
Primary completionActual
Jan 1, 2018
CompletionActual
Aug 30, 2020
Last update
Mar 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04793087
Responsible party
Sponsor
First posted
Mar 11, 2021
Start date
Jan 1, 2018
Primary completion
Jan 1, 2018
Completion
Aug 30, 2020
Last update
Mar 15, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion